Abstract: The present invention relates in a first aspect to a method for the purification of biological macromolecular complexes. Typically, no chromatography steps are applied. That is, the present invention relates to a method for the purification of biological macromolecular complexes Furthermore, the present invention relates to a method for crystallization of biological macromolecular complexes comprising the step of purification as described followed by crystallization in a reservoir solution containing a water-soluble polymer. Furthermore, purified biological macromolecular complexes obtainable by the method according to the present invention are provided as well as crystallized biological macromolecular complexes. Finally, a method for determining the suitability of a candidate compound for inhibiting the 20S proteasome of an individual is provided.

Abstract: The present invention relates to a compound of formula (I), wherein X is C?O, C?S or B—OH; Y is an electrophile and Z is a leaving group, or Y?Z is an electrophile; R1 comprises or consists of (a) (i) a first group binding to a proteolytic site of a proteasome, the first group being bound to X; and (ii) optionally a second group enhancing delivery; or (b) a group binding between subunits ?1 and ?2 of a proteasome; R2 and R3 are independently selected from H, methyl, methoxy, ethyl, ethenyl, ethynyl and cyano, wherein methyl and ethyl may be substituted with OH or halogen.

Abstract: In a first aspect, the present invention relates to new recombinant polypeptides derived from the newly identified gamma subunit of the fatty acid synthase protein complex. In addition, a fatty acid synthase protein complex comprising these new recombinant polypeptides are disclosed as well as nucleic acid molecules encoding these polypeptides. Further, a host cells containing the nucleic acid molecule encoding the polypeptides according to the present invention or expressing the polypeptide according to the present invention are described. In addition, an isolated fatty acid synthase protein complex is disclosed containing the newly identified gamma subunit thereof. Moreover, methods for determining the suitability of candidate compounds capable of inhibiting either the ketoreductase, enoylreductase or malonyl/palmitoyl transferase present in the FAS protein complex and methods for designing inhibitors of said enzymes are disclosed.

Abstract: The present invention relates in a first aspect to a method for the purification of biological macromolecular complexes. Typically, no chromatography steps are applied. That is, the present invention relates to a method for the purification of biological macromolecular complexes Furthermore, the present invention relates to a method for crystallization of biological macromolecular complexes comprising the step of purification as described followed by crystallization in a reservoir solution containing a water-soluble polymer. Furthermore, purified biological macromolecular complexes obtainable by the method according to the present invention are provided as well as crystallized biological macromolecular complexes. Finally, a method for determining the suitability of a candidate compound for inhibiting the 20S proteasome of an individual is provided.

Abstract: The present invention relates in a first aspect to a method for the purification of biological macromolecular complexes. Typically, no chromatography steps are applied. That is, the present invention relates to a method for the purification of biological macromolecular complexes Furthermore, the present invention relates to a method for crystallization of biological macromolecular complexes comprising the step of purification as described followed by crystallization in a reservoir solution containing a water-soluble polymer. Furthermore, purified biological macromolecular complexes obtainable by the method according to the present invention are provided as well as crystallized biological macromolecular complexes. Finally, a method for determining the suitability of a candidate compound for inhibiting the 20S proteasome of an individual is provided.

Abstract: The present invention relates to a compound of formula (I), wherein X is C?O, C?S or B—OH; Y is an electrophile and Z is a leaving group, or Y?Z is an electrophile; R1 comprises or consists of (a) (i) a first group binding to a proteolytic site of a proteasome, said first group being bound to X; and (ii) optionally a second group enhancing delivery; or (b) a group binding between subunits ?1 and ?2 of a proteasome; R2 and R3 are independently selected from H, methyl, methoxy, ethyl, ethenyl, ethinyl and cyano, wherein methyl and ethyl maybe substituted with OH or halogen.

Abstract: The present invention relates in a first aspect to a method for the purification of biological macromolecular complexes. Typically, no chromatography steps are applied. That is, the present invention relates to a method for the purification of biological macromolecular complexes Furthermore, the present invention relates to a method for crystallization of biological macromolecular complexes comprising the step of purification as described followed by crystallization in a reservoir solution containing a water-soluble polymer. Furthermore, purified biological macromolecular complexes obtainable by the method according to the present invention are provided as well as crystallized biological macromolecular complexes. Finally, a method for determining the suitability of a candidate compound for inhibiting the 20S proteasome of an individual is provided.

Abstract: In a first aspect, provided herein is a method of determining assembly, homogeneity and/or thermodynamic stability of biological macromolecular complexes. In particular, the method allows determining maximum stability of the complexes based on fluorescence changes at an appropriate wavelength as a function of temperature whereby the fluorescence changes reflect the status of assembly, homogeneity and/or thermodynamic stability of the biological macromolecular complexes. The method is based on identifying two state and multistate unfolding fluorescence curves as a function of temperature by fitting the curves according to a multistate unfolding model. In addition, a computer program and a computer program storage medium as well as an apparatus and a system is provided for determining the assembly, homogeneity and/or thermodynamic stability of biological macromolecular complexes.

Abstract: In a first aspect, the present invention relates to a method of determining assembly, homogeneity and/or thermodynamic stability of biological macromolecular complexes. In particular, the method allows determining maximum stability of said complexes based on fluorescence changes at an appropriate wavelength as a function of temperature whereby said fluorescence changes reflect the status of assembly, homogeneity and/or thermodynamic stability of the biological macromolecular complexes. Said method is based on identifying two state and multistate unfolding fluorescence curves as a function of temperature by fitting said curves according to a multistate unfolding model. In addition, a computer program and a computer program storage medium as well as an apparatus and a system is provided for determining the assembly, homogeneity and/or thermodynamic stability of biological macromolecular complexes.